-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the latest batch of "Nature" papers went online as scheduled.
This study is aimed at sickle cell disease (SCD).
No matter which method is used, good results have been achieved in clinical trials, and a functional cure for SCD can be achieved.
This paper provides a brand new idea.
From a rare hemoglobin variant in Indonesia, researchers have found new ideas.
In human cells, the researchers conducted a proof-of-concept.
▲Single-base editing of mouse hematopoietic stem cells can reverse their symptoms (picture source: reference [1])
▲Single-base editing of mouse hematopoietic stem cells can reverse their symptoms (picture source: reference [1])In another experiment, the researchers isolated hematopoietic stem and progenitor cells from a humanized SCD mouse model, performed single-base editing, and then fed these cells into irradiated mice.
Note: The original text has been deleted
Reference materials:
Reference materials:[1] Newby, GA, Yen, JS, Woodard, KJ et al.
[1] Newby, GA, Yen, JS, Woodard, KJ et al.
[2] Relying on an ultra-rare variant, David Liu unveils a new approach to editing sickle cell, Retrieved June 2, 2021, from https://endpts.
com/relying-on-an-obscure-variant-david-liu -unveils-a-new-approach-to-editing-sickle-cell/